Search

Displaying results 6651 - 6660 of 6949 in total
  1. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the s...

  2. Drug

    Annamycin

    go.drugbank.com/drugs/DB06420
    Investigational

  3. Drug

    Tifacogin

    go.drugbank.com/drugs/DB06437
    Investigational

  4. Drug

    Resiniferatoxin

    go.drugbank.com/drugs/DB06515
    Investigational

    Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission

  5. Drug

    Rebimastat

    go.drugbank.com/drugs/DB06573
    Investigational

  6. Drug

    Bevasiranib

    go.drugbank.com/drugs/DB06642
    Investigational

    Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).

  7. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...

  8. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure.

    Categories: Angiotensin Receptor Antagonists, Angiotensin II receptor blockers (ARBs), plain
  9. Drug

    Budiodarone

    go.drugbank.com/drugs/DB05519
    Investigational

    Budiodarone (ATI-2042) is an antiarrhythmic related to amiodarone that is currently being studied in clinical trials.

  10. Drug

    rhGAD65

    go.drugbank.com/drugs/DB04963
    Investigational

    rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.